We dive into the growing off-label use of GLP-1 medications like Ozempic, Wegovy, and Mounjaro among people with type 1 diabetes. I'm joined by longtime diabetes advocate and healthcare executive Marie Schiller to explore the benefits, risks, and evolving research around these drugs. We discuss new studies, including the ADJUST-T1D trial, showing improved A1C, increased time in range, reduced insulin needs, and moderate weight loss—without major safety concerns. Marie shares her personal journey with GLP-1s, why they could be a game-changer when combined with AID systems, and the barriers to insurance coverage and FDA approval. The conversation also covers how people are accessing these medications, ongoing clinical trials, and the need for a multipronged treatment approach in type 1 care.   Join the Diabetech Newsletter   Learn about Omnipod 5 (today's sponsor)*   T1D Exchange Registry Sign up  (US residents only)   Watch This Episode On Youtube   Follow Diabetech: Instagram | Tik Tok | YouTube | Facebook | Threads   DISCLAIMER: This podcast is not medical advice and is for educational purposes only. Always consult with your doctor before making changes to your health care.    *10-day trial eligibility may vary. Full terms and conditions apply. Visit omnipod.com/diabetech for clinical disclaimers, terms and important safety information. The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.